UBS Downgrades Zentalis Pharma to Neutral, Lowers Price Target to $5
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Eliana Merle has downgraded Zentalis Pharma (NASDAQ:ZNTL) from Buy to Neutral and significantly lowered the price target from $28 to $5.
June 20, 2024 | 4:37 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
UBS analyst Eliana Merle downgraded Zentalis Pharma from Buy to Neutral and reduced the price target from $28 to $5, indicating a significant loss of confidence in the stock.
The downgrade from Buy to Neutral and the drastic reduction in the price target from $28 to $5 by UBS suggests a significant loss of confidence in Zentalis Pharma's future performance. This is likely to negatively impact the stock price in the short term as investors react to the lowered expectations.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100